![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![SPI Pharma Corp Ad](https://www.pharmacompass.com/image/flap/spi-pharma-corp-ad-w36-desktop-headergif-63893.gif)
![SPI Pharma Corp Ad](https://www.pharmacompass.com/image/flap/spi-pharma-corp-ad-w36-mobile-headergif-78265.gif)
Active Filter(s):
Details:
The Librax brand and generic market had US sales of approximately $105.9 million MAT for the most recent twelve months ending in July 2021 according to IQVIA Health.
Lead Product(s): Chlordiazepoxide,Clidinium
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle™ and Efurix as topical oncological treatments.
Lead Product(s): Chlordiazepoxide,Amitriptyline Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Limbitrol
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: MedQuímica Indústria Farmacêutica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 28, 2022